Stock FULC FULCRUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-15 pm EDT 		5-day change 1st Jan Change
8.25 USD +4.30% Intraday chart for Fulcrum Therapeutics, Inc. +8.70% +22.22%
May. 14 Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating MT
May. 14 Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating
MT
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15
MT
Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal
DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment
MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug
MT
Transcript : Fulcrum Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
Fulcrum Therapeutics : Corporate Presentation May 2024
PU
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
GL
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
DJ
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
GL
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy in The Lancet Neurology
AQ
Fulcrum Therapeutics to Participate in Upcoming May Conferences
GL
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
AQ
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
GL
Fulcrum Therapeutics, Inc. Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy in The Lancet Neurology
CI
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
GL
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
AQ
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
GL
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FULC Stock
  4. News Fulcrum Therapeutics, Inc.
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW